Published Papers
Carbon monoxide-loaded red blood cells ameliorate metabolic dysfunction-associated steatohepatitis progression via enhancing AMP-activated protein kinase activity and inhibiting Kupffer cell activation
Hiroki Yanagisawa,Hitoshi Maeda,Isamu Noguchi,Motohiko Tanaka,Naoki Wada,Taisei Nagasaki,Kazuki Kobayashi,Gai Kanazawa,Kazuaki Taguchi,Victor Tuan Giam Chuang,Hiromi Sakai,Hiroyuki Nakashima,Manabu Kinoshita,Hiroaki Kitagishi,Yasuko Iwakiri,Yutaka Sasaki,Yasuhito Tanaka,Masaki Otagiri,Hiroshi Watanabe,Toru Maruyama
Redox Biology 2024-10
Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis
Shusuke Kumazaki,Hayato Hikita,Yuki Tahata,Ji Hyun Sung,Kenji Fukumoto,Yuta Myojin,Sadatsugu Sakane,Kazuhiro Murai,Yoichi Sasaki,Kumiko Shirai,Yoshinobu Saito,Takahiro Kodama,Naruyasu Kakita,Hirokazu Takahashi,Hidenori Toyoda,Goki Suda,Eiichi Morii,Takashi Kojima,Takeshi Ebihara,Kentaro Shimizu,Yutaka Sasaki,Tomohide Tatsumi,Tetsuo Takehara
Alimentary Pharmacology & Therapeutics 2024-06-03
The serum tenascin C level is a marker of metabolic disorder-related inflammation affecting pancreatic cancer prognosis
Katsuhiko Sato,Hayato Hikita,Minoru Shigekawa,Kazumasa Soma,Ryohei Yamauchi,Jihyun Sung,Seiya Kato,Yoichi Sasaki,Shinnosuke Kudo,Kenji Fukumoto,Kumiko Shirai,Kazuhiro Murai,Yuki Tahata,Teppei Yoshioka,Akira Nishio,Yoshinobu Saito,Takahiro Kodama,Yutaka Sasaki,Tomohide Tatsumi,Tetsuo Takehara
Scientific Reports 2024-05-26
Mouse Type-I Interferon-Mannosylated Albumin Fusion Protein for the Treatment of Chronic Hepatitis
Yuki Minayoshi,Hitoshi Maeda,Keisuke Hamasaki,Taisei Nagasaki,Mei Takano,Ryo Fukuda,Yuki Mizuta,Motohiko Tanaka,Yutaka Sasaki,Masaki Otagiri,Hiroshi Watanabe,Toru Maruyama
Pharmaceuticals 2024-02-19
A randomized phase I / II study of vascular endothelial growth factor receptor peptide vaccines for patients with hepatocellular carcinoma
Yoko Yoshimaru,Katsuya Nagaoka,Kentaro Tanaka,Satoshi Narahara,Hiroki Inada,Sotaro Kurano,Takayuki Tokunaga,Estuko Iio,Takehisa Watanabe,Hiroko Setoyama,Masakuni Tateyama,Koji Yoshida,Takuya Tsunoda,Yusuke Nakamura,Motohiko Tanaka,Yutaka Sasaki,Yasuhito Tanaka
Hepatology Research 2023-11-29
Nitric oxide facilitates the targeting Kupffer cells of a nano-antioxidant for the treatment of NASH.
Hitoshi Maeda,Yu Ishima,Junji Saruwatari,Yuki Mizuta,Yuki Minayoshi,Shota Ichimizu,Hiroki Yanagisawa,Taisei Nagasaki,Kengo Yasuda,Shun Oshiro,Manabu Taura,Matthew J McConnell,Kentaro Oniki,Kayoko Sonoda,Tomohiko Wakayama,Manabu Kinoshita,Tsuyoshi Shuto,Hirofumi Kai,Motohiko Tanaka,Yutaka Sasaki,Yasuko Iwakiri,Masaki Otagiri,Hiroshi Watanabe,Toru Maruyama
Journal of controlled release : official journal of the Controlled Release Society 2022-01
MISC
A NOVEL SERUM BIOMARKER, CLUSTERIN, AND RELATED PREDICTIVE INDEX SCORING COULD BE AN EARLY PREDICTOR OF RESPONSE TO SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA.
Satoshi Narahara,Takehisa Watanabe,Katsuya Nagaoka,Nahoko Fujimoto,Kentaro Tanaka,Takayuki Tokunaga,Takeshi Kawasaki,Yoko Yoshimaru,Masakuni Tateyama,Hideaki Naoe,Motohiko Tanaka,Yutaka Sasaki,Yasuhito Tanaka
HEPATOLOGY 2020-11
当科における切除不能肝細胞癌に対するレンバチニブ治療の初期経験
田中健太郎,徳永尭之,楢原哲史,川崎剛,長岡克弥,瀬戸山博子,吉丸洋子,渡邊丈久,立山雅邦,田中基彦,佐々木裕
Liver Cancer Journal 2019-10-31
UPREGULATION OF SECRETORY CLUSTERIN IN RESPONSE TO SORAFENIB LINKS TO ACQUIRED TREATMENT RESISTANCE OF HEPATOCELLULAR CARCINOMA.
Satoshi Narahara,Takehisa Watanabe,Katsuya Nagaoka,Nahoko Fujimoto,Kentaro Tanaka,Takayuki Tokunaga,Takeshi Kawasaki,Yoko Yoshimaru,Masakuni Tateyama,Hideaki Naoe,Motohiko Tanaka,Yutaka Sasaki
HEPATOLOGY 2019-10
